Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG Secures Financing to Complete Development of STR001 in Sudden Sensorineural Hearing Loss and to prepare NDA filing in Europe

Strekin AG today Announces the Publication of Key in vivo Data on Mechanisms of STR001 in the Treatment of Sensorineural Hearing Loss

Medikamente gegen das Absterben von Haarzellen im Innenohr

Strekin AG Secures CHF 10 Million Financing for Further Development of STR001 in Sudden Hearing Loss

Strekin’s development candidate, STR001, obtains EU orphan drug designation for the treatment
of Sudden Sensorineural Hearing Loss

Strekin AG Presents Update on Phase 2 Development of STR001 and New Preclinical Data in Hearing Loss

Strekin AG announces the presentation of key STR001 data at the Conference on Molecular Biology of Hearing and Deafness, Cambridge UK

Strekin AG to develop the P38 MAPK inhibitor Pamapimod

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued.

Life Science Startup Company Strekin AG announces the launch of a Phase 2 clinical study of STR001 as a potential new treatment for hearing loss

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.